Delivery of temperature sensitive items including proteins and kits will be paused on 6/19 for the Juneteenth holiday. For urgent orders please contact customer service.
Telisotuzumab (ABT-700) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab induces apoptosis. Telisotuzumab can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .
Pamufetinib (TAS-115) is a potent VEGFR and hepatocytegrowthfactorreceptor (c-Met/HGFR)-targeted kinase inhibitor with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively.
Dihexa, an oligopeptide drug, is an orally active and blood-brain barrier-permeable angiotensin IV analog. Dihexa binds to hepatocytegrowthfactor (HGF) with high affinity (Kd=65 pM) and potentiates its activity at its receptor, c-Met. Dihexa exhibits excellent antidementia activity and improves cognitive function in animal models. Dihexa may have therapeutic potential as a treatment Alzheimer’s disease .
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocytegrowthfactor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Metreceptor-mediated cancer cell proliferation, migration, and invasion .
Fosgonimeton (ATH-1017) is a hepatocytegrowthfactorreceptor (c-Met/HGFR) agonist. Fosgonimeton has neuroprotective effects in both LPS (HY-D1056) -induced neuroinflammation and Aβ-induced AD models .
Pamufetinib (TAS-115) mesylate is a potent VEGFRand hepatocytegrowthfactorreceptor (c-Met/HGFR)-targeted kinase inhibitor, with IC50s of 30 and 32 nM for rVEGFR2 and rMET, respectively.
Norleual TFA, an angiotensin (Ang) IV analog, is a hepatocytegrowthfactor (HGF)/c-Met inhibitor with an IC50 of 3 pM. Norleual TFA is an AT4 receptor antagonist and exhibits potent antiangiogenic activities .
Val-Cit-amide-Ph-Maytansine is an antibody and bispecific antigen-binding mol. that bind hepatocytegrowthfactorreceptor c-Met (MET) or antibody-drug conjugates (ADCs) .
Taligantinib (Compound Example 70) is an orally active and selective dual inhibitor targeting vascular endothelial growthfactorreceptor 2 (VEGFR-2) and hepatocytegrowthfactorreceptor (c-Met). Taligantinib suppresses tumor angiogenesis and cell proliferation. Taligantinib is promising for research of solid tumors such as non-small cell lung cancer and hepatocellular carcinoma .
Norleual, an angiotensin (Ang) IV analog, is a hepatocytegrowthfactor (HGF)/c-Met inhibitor with an IC50 of 3 pM. Norleual is an AT4 receptor antagonist and exhibits potent antiangiogenic activities .
Foretinib phosphate is an orally bioavailable small molecule with potential anti-tumor activity. Foretinib phosphate can selectively inhibit hepatocytegrowthfactor (HGF) receptor c-MET and vascular endothelial growthfactorreceptor 2 (VEGFR2), thereby potentially inhibiting tumor angiogenesis, tumor cell proliferation and metastasis. Foretinib phosphate shows different anti-cancer activity from cabozantinib in lung cancer cells and has stronger inhibitory effects on targets such as MEK1/2, FER and AURKB .
Telisotuzumab (ABT-700) (powder) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab (powder) binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab (powder) induces apoptosis. Telisotuzumab (powder) can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocytegrowthfactor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET Y1235D is a mutant of MET. MET Y1235D Recombinant Human Active Protein Kinase is a recombinant MET Y1235D protein that can be used to study MET Y1235D-related functions .
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocytegrowthfactor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET G1163R is a mutant of MET. MET G1163R Recombinant Human Active Protein Kinase is a recombinant MET G1163R protein that can be used to study MET G1163R-related functions .
Human HGF mRNA encodes the human hepatocytegrowthfactor (HGF) protein, a protein that binds to the hepatocytegrowthfactorreceptor to regulate cell growth, cell motility and morphogenesis in numerous cell and tissue types. It also plays a role in angiogenesis, tumorogenesis, and tissue regeneration.
Val-Cit-amide-Cbz-N(Me)-Maytansine is an antibody and bispecific antigen-binding mol. that bind hepatocytegrowthfactorreceptor c-Met (MET) or antibody-drug conjugates (ADCs) .
PF 04254644 is an orally active c-Met inhibitor. PF 04254644 inhibits mesenchymal transfer factor/hepatocytegrowthfactorreceptor. PF 04254644 induces myocardial degeneration in rats. PF 04254644 may be used in research on cardiovascular disease and cancer .
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocytegrowthfactor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET Y1230A is a mutant of MET. MET Y1230A Recombinant Human Active Protein Kinase is a recombinant MET Y1230A protein that can be used to study MET Y1230A-related functions .
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocytegrowthfactor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET D1228N is a mutant of MET. MET D1228N Recombinant Human Active Protein Kinase is a recombinant MET D1228N protein that can be used to study MET D1228N-related functions .
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocytegrowthfactor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET D1228H is a mutant of MET. MET D1228H Recombinant Human Active Protein Kinase is a recombinant MET D1228H protein that can be used to study MET D1228H-related functions .
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocytegrowthfactor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET Y1230C is a mutant of MET. MET Y1230C Recombinant Human Active Protein Kinase is a recombinant MET Y1230C protein that can be used to study MET Y1230C-related functions .
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocytegrowthfactor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET L1195V is a mutant of MET. MET L1195V Recombinant Human Active Protein Kinase is a recombinant MET L1195V protein that can be used to study MET L1195V-related functions .
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocytegrowthfactor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET Y1230D is a mutant of MET. MET Y1230D Recombinant Human Active Protein Kinase is a recombinant MET Y1230D protein that can be used to study MET Y1230D-related functions .
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocytegrowthfactor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET Y1230H is a mutant of MET. MET Y1230H Recombinant Human Active Protein Kinase is a recombinant MET Y1230H protein that can be used to study MET Y1230H-related functions .
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocytegrowthfactor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET M1250T is a mutant of MET. MET M1250T Recombinant Human Active Protein Kinase is a recombinant MET M1250T protein that can be used to study MET M1250T-related functions .
FGFR3-IN-11(compound B11) is a Fibroblast growthfactorreceptor 3 (FGFR3) inhibitor with a Ka value of 4.8 μM. FGFR3-IN-11 induces apoptosis, suppresses colony formation, and causes dose-dependent G0/G1 cell cycle arrest in cancer cells. FGFR3-IN-11 exerts anticancer activity against cancer cells with minimal toxicity toward normal hepatocytes and demonstrates tumor growth suppression in xenograft mouse models. FGFR3-IN-11 can be used for the research of hepatocellular carcinoma .
Mesenchymal-to-epithelial transition (MET) is a receptor tyrosine kinase for hepatocytegrowthfactor (HGF). MET overactivation is strongly associated with angiogenesis, cellular motility, growth, and invasion. Aberrant MET signaling can drive tumorigenesis in several cancer types through various molecular mechanisms, including MET amplification, MET exon 14 skipping mutation, MET overexpression, and MET fusions. MET F1200I is a mutant of MET. MET F1200I Recombinant Human Active Protein Kinase is a recombinant MET F1200I protein that can be used to study MET F1200I-related functions .
Norleual TFA, an angiotensin (Ang) IV analog, is a hepatocytegrowthfactor (HGF)/c-Met inhibitor with an IC50 of 3 pM. Norleual TFA is an AT4 receptor antagonist and exhibits potent antiangiogenic activities .
Norleual, an angiotensin (Ang) IV analog, is a hepatocytegrowthfactor (HGF)/c-Met inhibitor with an IC50 of 3 pM. Norleual is an AT4 receptor antagonist and exhibits potent antiangiogenic activities .
Telisotuzumab (ABT-700) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab induces apoptosis. Telisotuzumab can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .
Ficlatuzumab is a monoclonal antibody (McAb) targeting human hepatocytegrowthfactor (HGF). Ficlatuzumab blocks the activation of the HGF/c-Met signaling pathway, and inhibits c-Metreceptor-mediated cancer cell proliferation, migration, and invasion .
Telisotuzumab (ABT-700) (powder) is a bivalent humanized IgG1 anti-c-Met monoclonal antibody. Telisotuzumab (powder) binds cellular c-Met and disrupts its productive dimerization and activation induced by HGF or by the high density of c-Met on the cell surface independent of ligand. Telisotuzumab (powder) induces apoptosis. Telisotuzumab (powder) can be used for the study of cancers harboring amplified MET, such as gastric and lung cancers .
HGFR Protein is a receptor tyrosine kinase that acts as a signal transducer of the extracellular matrix by binding to hepatocyte growth factor /HGF ligands. HGFR Protein participate in the activation of RAS-ERK, PI3 kinase-AKT, and PLCgamma-PKC signaling pathways. HGFR Protein is essential for embryonic development, organogenesis, and wound healing. HGFR Protein, Rat (HEK293, Fc) is the recombinant rat-derived HGFR protein, expressed by HEK293 , with C-hFc labeled tag.
The HGFR protein is a receptor tyrosine kinase that transduces signals by binding to hepatocyte growth factor/HGF. It regulates proliferation, scattering, morphogenesis, and cell survival. HGFR Protein, Canine (HEK293, Fc) is the recombinant canine-derived HGFR protein, expressed by HEK293, with C-hFc labeled tag.
HGFR Protein, a receptor tyrosine kinase, transduces signals by binding hepatocyte growth factor/HGF ligand. It regulates proliferation, scattering, morphogenesis, and cell survival. Upon ligand binding, HGFR undergoes autophosphorylation, creating docking sites for downstream molecules like PI3K, PLCG1, SRC, GRB2, STAT3, or GAB1, activating RAS-ERK, PI3K-AKT, and PLCgamma-PKC cascades. HGFR Protein, Cynomolgus/Rhesus Macaque (HEK293) is the recombinant Rhesus Macaque, cynomolgus-derived HGFR protein, expressed by HEK293 , with tag free.
The HGFR protein is a receptor tyrosine kinase that transduces signals by binding to hepatocyte growth factor/HGF. It regulates proliferation, scattering, morphogenesis, and cell survival. HGFR Protein, Canine (HEK293, His) is the recombinant canine-derived HGFR protein, expressed by HEK293 , with N-His labeled tag.
The HGFR protein is a receptor tyrosine kinase that transduces signals from the extracellular matrix by binding to hepatocyte growth factor/HGF ligand. This interaction regulates proliferation, scattering, morphogenesis, and cell survival. HGFR Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived HGFR protein, expressed by HEK293 , with C-hFc labeled tag.
The HGFR protein is a receptor tyrosine kinase that transduces signals by binding to hepatocyte growth factor/HGF ligand. It regulates proliferation, scattering, morphogenesis, and cell survival. HGFR Protein, Human (sf9, His-GST) is the recombinant human-derived HGFR protein, expressed by Sf9 insect cells , with N-His, N-GST labeled tag.
The HGFR protein is a receptor tyrosine kinase that transduces signals by binding to hepatocyte growth factor/HGF ligand. It regulates proliferation, scattering, morphogenesis, and cell survival. HGFR Protein, Human (Active, D1228N, sf9, His-GST) is the recombinant human-derived HGFR protein, expressed by Sf9 insect cells , with N-His-GST labeled tag.
The HGFR protein is a receptor tyrosine kinase that transduces signals by binding to hepatocyte growth factor/HGF ligand. It regulates proliferation, scattering, morphogenesis, and cell survival. HGFR Protein, Human (HEK293, His) is the recombinant human-derived HGFR protein, expressed by HEK293 , with C-6*His labeled tag.
The HGFR protein is a receptor tyrosine kinase that transduces signals by binding to hepatocyte growth factor/HGF ligand. It regulates proliferation, scattering, morphogenesis, and cell survival. HGFR Protein, Human (HEK293, Fc) is the recombinant human-derived HGFR protein, expressed by HEK293 , with C-hFc labeled tag.
The HGFR protein is a receptor tyrosine kinase that transduces signals by binding to hepatocyte growth factor/HGF ligand. It regulates proliferation, scattering, morphogenesis, and cell survival. HGFR Protein, Human (495a.a, HEK293, His) is the recombinant human-derived HGFR protein, expressed by HEK293 , with C-6*His labeled tag.
The HGFR protein is a receptor tyrosine kinase that transduces signals by binding to hepatocyte growth factor/HGF ligand. It regulates proliferation, scattering, morphogenesis, and cell survival. HGFR Protein, Human (Biotinylated, HEK293, His-Avi) is the recombinant human-derived HGFR protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag.
Phospho-c-Met (Tyr1234/1235) Antibody (YA5844) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-c-Met (Tyr1234/1235).
MET; hepatocytegrowthfactorreceptor; HGF receptor; HGF/SF receptor; Proto-oncogene c-Met; Scatter factorreceptor; SF receptor; Tyrosine-protein kinase Met
WB, IP
Human
Phospho-Met（c-Met） (Tyr1349) Antibody (YA213) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-Met（c-Met） (Tyr1349).
MET; hepatocytegrowthfactorreceptor; HGF receptor; HGF/SF receptor; Proto-oncogene c-Met; Scatter factorreceptor; SF receptor; Tyrosine-protein kinase Met
WB, IP
Human
Phospho-Met（c-Met） (Tyr1349) Antibody (YA213) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-Met（c-Met） (Tyr1349).
Human HGF mRNA encodes the human hepatocytegrowthfactor (HGF) protein, a protein that binds to the hepatocytegrowthfactorreceptor to regulate cell growth, cell motility and morphogenesis in numerous cell and tissue types. It also plays a role in angiogenesis, tumorogenesis, and tissue regeneration.
온라인 문의
Your information is safe with us. * Required Fields.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
MedchemExpress Validation 03
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
MedchemExpress Validation 04
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website.
Privacy and Cookie Policy
